Literature DB >> 3871450

Chronic progressive polyarthritis and other symptoms of collagen vascular disease induced by graft-vs-host reaction.

S T Pals, T Radaszkiewicz, L Roozendaal, E Gleichmann.   

Abstract

The induction of a GVHR in (BALB/c X A)F1 mice by i.v. injection of 80 to 120 X 10(6) BALB/c spleen cells leads to the development of chronic progressive polyarthritis, which shares several of the articular and extra-articular manifestations of human rheumatoid arthritis. The development of these lesions was found to be mediated by donor T cells and to require the presence of histoincompatibility between donor and host. The arthritis, which was mainly confined to the interphalangeal joints of the forefeet and hindfeet, was histologically characterized by periarticular and synovial lymphoid infiltrations, as well as synovial proliferation and pannus formation. Prominent juxta-articular lesions included 1) perivascular infiltrates, 2) peritendinitis, 3) myositis, and 4) inflammatory nodules. In addition, the GVH F1 mice showed pathologic symptoms reminiscent of other collagen vascular diseases, including the following: 1) a Sjögren-like salivary gland lesion, 2) lesions resembling sclerosing cholangitis, 3) scleroderma-like skin lesion, and 4) immune-complex glomerulonephritis. In most of the GVH F1 mice, these pathologic changes were accompanied by lymphoid stimulation. The spectrum of symptoms induced has many similarities to that found in mixed connective tissue disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871450

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Persistence of allospecific helper T cells is required for maintaining autoantibody formation in lupus-like graft-versus-host disease.

Authors:  L Rozendaal; S T Pals; E Gleichmann; C J Melief
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 2.  Advances in lupus stemming from the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Trends Immunol       Date:  2010-03-31       Impact factor: 16.687

Review 3.  T cells, murine chronic graft-versus-host disease and autoimmunity.

Authors:  Robert A Eisenberg; Charles S Via
Journal:  J Autoimmun       Date:  2012-06-16       Impact factor: 7.094

4.  Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice.

Authors:  R Yung; D Powers; K Johnson; E Amento; D Carr; T Laing; J Yang; S Chang; N Hemati; B Richardson
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

5.  Successful transfer of collagen-induced arthritis to severe combined immunodeficient (SCID) mice.

Authors:  R O Williams; C Plater-Zyberk; D G Williams; R N Maini
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

6.  Spontaneous autocytotoxicity against an unexpected H-2d haplotype in MRL/lpr (H-2k) autoimmune disease-prone mice.

Authors:  P Bobé; G Gachelin; N Kiger
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

7.  CD4+ T cells from collagen-induced arthritic mice are essential to transfer arthritis into severe combined immunodeficient mice.

Authors:  K M Kadowaki; H Matsuno; H Tsuji; I Tunru
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

Review 8.  Mouse models of graft-versus-host disease: advances and limitations.

Authors:  Mark A Schroeder; John F DiPersio
Journal:  Dis Model Mech       Date:  2011-05       Impact factor: 5.758

9.  Thymus and autoimmunity: capacity of the normal thymus to produce pathogenic self-reactive T cells and conditions required for their induction of autoimmune disease.

Authors:  S Sakaguchi; N Sakaguchi
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

10.  T Cell Integrin Overexpression as a Model of Murine Autoimmunity.

Authors:  Raymond L. Yung; Donna Ray; Ru Ran Mo; Jun Chen
Journal:  Biol Proced Online       Date:  2003-10-24       Impact factor: 3.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.